A current concept of the serological response to human immunodeficiency virus (HIV) infection in humans is that antibodies to core antigens (p55, p24, and piS) are detectable earlier during initial stages of antibody production than antibodies against envelope antigens (gpl60, gpl20, and gp4l). Comparative studies of Western blot (immunoblot), radioimmunoprecipitation assay (RIPA), and enzyme-linked immunosorbent assay (ELISA) during initial antibody production are limited to case reports and have not resolved the issue. Thirty of the 37 participants who are part of a prospective study had at least one specimen that was negative for anti-gp4l but had one or more other bands on Western blot. Twenty-seven of these 30 specimens were reactive for anti-gpl20/160 in the RIPA. Of the same 30 specimens, kits from Bionetics identified 2 (7%), ElectroNucleonics 4 (13%), Abbott 13 (43%), Du Pont 25 (83%), and Genetic Systems 25 (83%). All participants had evidence of serological progression by Western blot, including a gp4l band, on subsequent visits; the ELISA kits of all manufacturers identified these later specimens with greater accuracy. These data show that the RIPA detects anti-envelope antibodies that may be not detectable by Western blot and that the production of anti-envelope antibodies approximately parallels the production of anti-core antibodies. The false-negative results by ELISA would permit transmission of HIV by blood transfusion from donors in early stages of infection. The sensitivity of licensed ELISA kits should be improved to identify antibody as soon as possible after infection.
The acquired immunodeficiency syndrome (AIDS) was first described in 1981 as a disease of homosexual and bisexual men (4) and was later found in intravenous drug users, hemophiliacs (5) , and recipients of blood transfusion (6) . The probable etiological agent was identified as a retrovirus and described in reports from France (2) and the United States (9) . In this report, the retrovirus is referred to as human immunodeficiency virus (HIV) (J. Coffin, A. Haase, J. A. Levy, L. Montagnier, S. Oroszlan, N. Teich, H. Temin, K. Toyoshima, H. Varmus, P. Vogt, and R. Weiss, Letter, Science 232: 697, 1986 ). An enzyme-linked immunosorbent assay (ELISA) was developed to test serum or plasma specimens for antibodies to the retrovirus (11) and was subsequently licensed in March 1985 to screen blood donors for such antibodies. Blood that is repeatably reactive in the ELISA is, in most instances, retested by Western blot (WB) (immunoblot) as a confirmatory test (13) .
The strategy for selecting antigens for candidate vaccines and for serodiagnostic reagents depends on understanding the natural history of antibody production. A widely held belief concerning the serological response to HIV infection in humans is that antibodies to core antigens (p55, p24, and pi5) are detectable earlier than antibodies against envelope antigens (gpl6O, gpl20, and gp4l) during the initial stages of antibody production (5, 9, 16) . In general, the WB and the radioimmunoprecipitation assay (RIPA) favor detecting anticore and anti-envelope antibodies, respectively (17). The primacy of antibody production is therefore best described by testing sera in both systems. However 2 for a reactive band, and 3 for a strongly reactive band. The scores of all bands were added, and a value of .3 defined a positive immunoblot, 2 defined an equivocal blot, and '1 defined a negative blot. Equivocal blots were sometimes reclassified based on the results of serial specimens.
The contention that anti-envelope antibodies may be absent in gp41-negative specimens was tested with the RIPA. Serial specimens from participants who were shown by WB to be infected were sent to the Harvard School of Public Health for RIPA (1) . Specimens were tested, and results were reported under code.
Serial specimens from three WB-confirmed seropositive and seven WB-confirmed seronegative controls were included with the test specimens of the 59 participants who were studied.
RESULTS
All positive and negative control specimens were accurately identified by each ELISA kit, WB, and RIPA. Sixteen of 59 participants were found to be totally negative (no bands) by WB. These 16 participants were selected for longitudinal testing because they had previously shown either isolated, weak p24 reactivity on a single WB blot (n = 11) or a negative blot with a concomitant positive ELISA test (n = 5). Six other subjects had one or more bands to core antigens but showed no serological progression in the WB and could not be confirmed as truly infected with HIV. The 37 remaining subjects demonstrated progression of seroreactivity in the WB. Twenty-eight of these men were positive at their initial visit and were in an early stage of HIV infection according to their WB pattern and subsequent course (5, 9, 16 ). The remaining nine men were seroconverters by WB between their first and second visits; the mean interval was 209 days (range, 181 to 237 days). Each had a third visit (approximately 12 months after visit 1) that showed a fully developed WB (many bands, including gp4l). The subsequent broadly positive WBs showed that earlier specimens lacking measurable antibody to gp4l did in fact represent HIV infection in each instance. In seven cases, a subsequent broadly reactive WB that included at least a reactive gp4l band was used to interpret a prior equivocal blot. Figure 1 shows representative examples of blot progression. Six of these seven were single blots that occurred just prior to the strongly positive blot. In the remaining case a sole, weakly reactive p24 band progressed to a strongly reactive p24 band 6 months later and progressed further to include a reactive gp4l band 12 months after the first blot.
The weak reactivity against p24 on the first blot was considered evidence of infection at the first visit. Each of the three longitudinal serum samples from this participant was nega- tive by RIPA, whereas in specimens from the other 36 participants, subsequent ELISAs and RIPAs were positive. This inconsistent finding raises the question of a falsely reactive WB for gp4l at the third visit (see Discussion).
Seropositives at initial visit. Table 1 presents a summary of ELISA results by kit and the corresponding reactivity of gp4l in the WB for men whose visit 1 specimens were positive by WB. Twenty-three of these 28 subjects had no detectable antibody to gp4l; of these 23 sera, RIPA identified 20 (87%) as having anti-envelope antibodies (gpl20/160). Du Pont and Genetic Systems kits correctly identified 18 of these 23. Each of these two kits missed one specimen that the other correctly identified as positive. The WBs of the two specimens were not perceptibly different; each was reactive for p24. Three of the remaining four blots had a faint to strongly reactive p24 band as a sole band; the remaining blot had a reactive pi5 band and a faint p64 band.
Of the five participants who had a reactive gp4l band at their first visit, all were positive by RIPA and three were missed by both Bionetics and ENI kits. Both of these kits missed the same specimens, and the one specimen that the Abbott kit missed was also missed by the Bionetics and ENI kits. The degree of agreement in the missed specimens prompted an investigation of possible peculiarities in these blots. Two of the three blots had only two bands present: a strongly reactive p24 and a reactive gp4l. The specimen missed by the Abbott kit was one of these. The remaining blot had the latter bands plus three reactive bands against p53, p55, and p64.
Seroconverters at visit 2. Almost identical results were seen in the visit 2 specimens from the seroconverters ( Table  2 ). More than 70% (5 or 6 of 7) of anti-gp4l-negative specimens were missed by kits from Abbott, Bionetics, and ENI. The Du Pont and Genetic Systems kits, however, identified all seven of these seroconverter specimens as positive. Bionetics and ENI kits agreed in identifying the single specimen out of seven that they determined was positive. This specimen gave a strongly reactive p24 and a reactive p53 reaction in its blot. It was reactive by the other kits as well. Note, in Tables 1 and 2 , that subsequently obtained specimens showed stronger gp4l bands and that the different ELISA kits performed comparably. However, by this time many other bands had also become strongly positive and may have contributed to the similarity of reactivity in the various ELISA kits. In the RIPA, all visit 2 specimens were positive, whether anti-gp4l was present or not. Also, a visit 1 (preconversion) specimen was positive by RIPA (see Discussion).
Combined groups. Table 3 combines data for visit 1 of those who were initially positive and visit 2 of those who seroconverted. This table summarizes the performance of each ELISA kit in identifying specimens from participants with evolving seroreactivity. Reactivity in all kits was correlated with WB reactivity to gp4l, especially in kits from Abbott, Bionetics, and ENI, but many other bands were present as well.
The RIPA identified anti-gpl20/160 antibodies in 27 of the 30 specimens that were negative for anti-gp4l in the WB. The RIPA accurately identified all specimens that were positive for anti-gp4l in the first positive WB and all subsequently reactive WBs except one.
The criteria for a positive reaction for the five ELISA kits (Table 4) . Repeatability, i.e., confirmation, of true-positive reactions also was examined. With the kits of Abbott, Genetic Systems, and Bionetics, all initially positive reactions were repeatable, indicating that the single-repeat algorithm for Genetic Systems and Bionetics had no effect on the overall results (see above). The Du Pont kit gave a positive reaction that became negative on repeat testing in one WB-positive individual from visit 1. The ENI kit did this for seven participants from visit 1 and two from visit 2.
DISCUSSION
Experience with the WB is extensive because it is used to confirm reactivity in the ELISA. Antibodies to core antigens have been described as rising prior to antibodies against envelope antigens. This study demonstrates that antienvelope antibodies are present even though they may not be detected by WB. It is also apparent that potential blood donors with early infection lack sufficient levels of anti-gp4l and other antibodies to be consistently reactive in the currently licensed test kits yet are positive by both WB and RIPA. These results extend in two ways those of Reesink et al. (10) , who tested ELISA kits marketed in Europe. First, they found that, compared with WB, the kits studied were less sensitive in identifying sera from asymptomatic HIVinfected individuals than in identifying sera from AIDS Genetic Systems 25 (83) 7 (100) patients. The authors characterized sera from asymptomatic individuals as p24 predominant and those from AIDS patients as gp4l predominant by testing the kits with serial dilutions of sera. In our study it was shown that the sensitivity of U.S. ELISA kits during the early stages of antibody production ranged from similar to to worse than that found in a study with serial dilutions. Second, the WB characterization of p24 and gp4l as predominant may be useful, but it is not altogether correct because anti-envelope (gpl20/160) antibodies are present in both types of sera. ELISA kits. The proportion of gp41-negative participants whose evolving specimens were identified in this study ranged from a low of 7% for Bionetics to a high of 83% for Du Pont and Genetic Systems. While antibody to gp4l seems to be important (J. R. Carlson, S. H. Hinrichs, N. B. Levy, M. B. Gardner, P. Holland, and N. C. Pedersen, Letter, Lancet i: 1388, 1985) , specimens that were missed in spite of reactivity to gp4l seem to indicate that higher-grade reactivity to other antigens may also be required before some ELISA kits become reactive. More intense and broader reactivity is presumably due to longer duration of infection than was present in these men when they initially became anti-gp4l positive.
An intriguing observation from this study was that specimens were not missed randomly. When one kit incorrectly identified a specimen as negative, there was usually at least one other kit, and often several others, that also produced false-negative results with the same specimen. Such consistency in these results essentially rules out a problem with one or another lot of kits as an explanation for the results and indicates a fundamental problem with the ability of certain (Table  2) . Specimens from these participants were selected solely because they had no or minimal reactivity to gp4l on WB. Furthermore, specimens that were selected based on discrepant ELISA results, such as those positive at visit 1, were selected from the population of men who were in the early stages of infection (estimated to be 100 participants), not from the population of strongly seropositive participants (1, 880 
